If what you say is true, and this is how they propose to run a Phase 2b Alzheimer's trial, then I can understand why they haven't been able to get approval to run a trial in the US.
Pre-specifying interim statistical analysis is such a no-brainer that the FDA would shake their head and say try again.
News 
Market Data 
Discover 
AI
